Amanda Anderson-Pleiss, NP
Acute Care · Lakewood, CONPI 1467045435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$630
- Sanofi$591
- Grifols USA, LLC$389
- Regeneron Healthcare Solutions, Inc.$370
- Boehringer Ingelheim$232
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,759100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $1,097 |
| GSK | 31 | $630 |
| Sanofi | 33 | $591 |
| Grifols USA, LLC | 27 | $389 |
| Regeneron Healthcare Solutions, Inc. | 18 | $370 |
| Boehringer Ingelheim | 10 | $232 |
| Bayer | 5 | $212 |
| Inari Medical, Inc. | 1 | $114 |
| Inspire Medical Systems, Inc. | 2 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $89 |
| Harmony Biosciences LLC | 2 | $85 |
| Jazz Pharmaceuticals Inc. | 3 | $74 |
| Amgen | 3 | $73 |
| Baxter Healthcare | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Pharming Healthcare, Inc. | 2 | $54 |
| Philips North America LLC | 3 | $53 |
| Pulmonx Corporation | 2 | $51 |
| United Therapeutics Corporation | 2 | $51 |
| AbbVie | 2 | $43 |
| Inogen, Inc. | 1 | $42 |
| Medtronic | 1 | $27 |
| Insmed, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Sandoz | 1 | $24 |
| Mylan Specialty L.p. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Optinose US, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Liquidia Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$125
- TAGRISSO$125
- NUCALA$122
- Adempas$122
- FLOWTRIEVER CATHETER, S$114
- CT THROMBECTOMY SYSTEM KIT$114
How this compares
$4,759 in reported general payments places this provider in the 90th percentile of 239 acute care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 14 | $188,716 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 169 | $162,318 |
| EliquisApixaban | 103 | $89,303 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 114 | $87,577 |
| Dupixent PenDupilumab | 15 | $62,205 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $56,125 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $41,039 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $19,605 |
| Spiriva HandihalerTiotropium Bromide | 11 | $17,429 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $16,330 |
| XareltoRivaroxaban | 13 | $14,245 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $4,543 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 149 | $4,057 |
| Ventolin HfaAlbuterol Sulfate | 41 | $2,916 |
| Azithromycin | 71 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $232 | $244,841102 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $630 | $222,962270 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,097 | $103,906152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 239 acute care providers in Colorado.
Other acute care in Lakewood
- Bethany LombardoLakewood$1K
- Tiffany MorganColorado Springs$590K
- Wendy StevensCortez$57K
- Peter ByrneLone Tree$56K
- Paige YountColorado Springs$26K
- Sarah NorwoodColorado Springs$20K
- Rachele RobertsAurora$19K
- Shari Nieman CorsoLittleton$14K
- Lauren SpitzingerDenver$13K
- Gregory CharlestonPueblo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.